CancerNetwork Members: Login | Register
Become a fan on Facebook  Add us on Google Plus Follow us on Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 
 
NEWS

Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
May 20, 2013
FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
May 16, 2013
In NSCLC, Beta-3 Tubulin Isoform Does Not Predict Treatment Response to Ixabepilone, Paclitaxel
May 13, 2013
HER2-Targeted Therapies Could Benefit Lung Cancer Patients With HER2 Mutations
May 1, 2013
Smoking Immediately After Waking Correlates With Higher Carcinogen Levels
April 9, 2013

 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Lung Cancer
 
REVIEW ARTICLES

ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time
Hatim Husain, MD1, Charles M. Rudin, MD, PhD1 , June 14, 2011

Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation.
• ALK-Targeted Therapy in NSCLC: Not Quite Ready for Prime Time
• The Future of NSCLC: Molecular Profiles Guiding Treatment Decisions

How Long Have I Had My Cancer, Doctor?
Michael V. Patrone1, Jessica L. Hubbs, MS2,
Janet E. Bailey, BA3, Lawrence B. Marks, MD3 , January 24, 2011

To estimate the “age” of cancers, we reviewed data on the “time to local/regional recurrence” (LRF) following initial surgical resection for three common cancers, then applied a modified version of Collins’ law.
• Influences on the Natural History of Cancers
• Kinetics of Cancer: Implications from Prevention to Prognostication
• Cancer Age: Can We Reliably Estimate and Apply This Knowledge?

Lung Cancer Management in 2010
Apar Kishor Ganti, MD1, Chao H. Huang, MD2, Mark A. Klein, MD3, Sean Keefe, PharmD, BCOP4, Michael J. Kelley, MD5 , January 21, 2011

Exciting advances in understanding the biology of lung cancer have occurred over the last few years. These advances have led to the design of trials exploring the clinical value of newer treatment approaches.
• Lung Cancer: New Developments Point the Way to Reduced Mortality
• Putting Lung Cancer Clinical Trials Into Perspective

Unanswered Questions: Monoclonal Antibodies in the Treatment of Advanced Non–Small-Cell Lung Cancer
Cesare Gridelli, MD1, Antonio Rossi, MD1 , December 17, 2010

Despite the fact that bevacizumab and cetuximab are both in an advanced stage of clinical development for use in treatment for unresectable NSCLC, several unanswered questions regarding these drugs remain.
• Bevacizumab: In Search of the Right Drug for the Right Patient
• Future Directions of Monoclonal Antibody Use in Personalized Therapy

Lung Cancer After 70: Is it a Different Disease?
Daniel J. Lebovic, MD1, Tariq Mahmood, MD2, Alberto Chiappori, MD3 , November 8, 2010

Our knowledge regarding the efficacy and safety of chemotherapy in elderly patients is suboptimal, yet those with advanced NSCLC demonstrate the same response rates and survival benefits as their younger peers.
• Lung Cancer in the Elderly—What’s Age Got to Do With It?
• Youth Has No Age—Cancer Treatment for Older Americans

Showing 6 - 10 of 20 results.
Page of 4
First Last
 
 
IMAGE IQ

A 49-Year-Old Woman Develops Thickened and Bound-Down Skin
May 13, 2013

A 49-year-old woman insidiously developed spotty depigmentation of the chest along with thickened and bound-down skin of the upper torso. In addition, all of her fingers were swollen and her facial skin became so tight that she had difficulty smiling. What is her diagnosis?

NSCLC Patient Develops Erythema After Vancomycin Infusion
April 22, 2013

A 71-year-old man with a smoking history of more than 100 pack-years developed non–small-cell carcinoma of the lung. During his an infusion of vancomycin he developed flushing, followed by widespread fixed erythema, muscular spasms in the back, and transient but severe hypotension. Can he ever receive vancomycin again?

Pleural Nodules Discovered in 34-Year-Old Woman
February 7, 2013

A 34-year-old woman presents with pain in her left chest. Radiographic imaging shows the presence of nodules in the pleural surface. Surgical excision is performed. What is your diagnosis?

 
CLINICAL TRIALS
LAB-IMMUNOLOGY RESEARCH
neuro-oncology.oxfordjournals.org - 11/4/12
Clinical Year in Review II: Mechanical Ventilation, Acute Respiratory Distress Syndrome, Critical Care, and Lung Cancer
pats.atsjournals.org - 9/29/12
Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data
neuro-oncology.oxfordjournals.org - 8/20/12
Idiopathic Pulmonary Fibrosis: An Altered Fibroblast Proliferation Linked to Cancer Biology
pats.atsjournals.org - 7/14/12
A nomogram for individualized estimation of survival among patients with brain metastasis
neuro-oncology.oxfordjournals.org - 6/19/12

Result Pages: 1 2 3 4 5 Next


 
More Features
May 17, 2013
Helping NSCLC Patients to Fight Fatigue with Fitness
A new program to fight post-thoractoromy fatigue, and insights into how late-stage lung cancer patients perceive the advice to remain active. More »
May 16, 2013
FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
The FDA approved a label expansion for erlotinib (Tarceva), along with the cobas EGFR mutation diagnostic test, to include patients untreated... More »
May 15, 2013
New Targets and New Mechanisms in Lung Cancer
This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used... More »
May 15, 2013
Adapting to the Brave New World of Lung Cancer Treatment
If we are to provide new options for the large numbers of NSCLC patients with no actionable mutation, we must focus on identifying new mutations... More »
May 13, 2013
In NSCLC, Beta-3 Tubulin Isoform Does Not Predict Treatment Response to Ixabepilone, Paclitaxel
Expression of the beta-3 tubulin (ß3T) isoform was a negative prognostic factor in non–small-cell lung cancer (NSCLC) patients, but did not predict... More »
Showing 1 - 5 of 1,242 results.
Page of 249
First Previous Last

 
TOPIC INDEX

Cancer Types

  

Supportive Care

More Topics


All Topics 


 
PODCASTS

AACR: Lung Cancer Therapy Innovations
Julie R. Brahmer, MD1 , April 5, 2013

In this interview, ahead of the AACR annual meeting, we speak with Dr. Julie Brahmer, of Johns Hopkins School of Medicine, who is giving a presentation on immunotherapy in lung cancer, and is one of the clinical investigators of the extensive phase I trial of the anti–PD-1 antibody nivolumab.

 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 
 
COMMENTS